## 103rd Session of the TDR Standing Committee
Indian Room, WHO Headquarters, Geneva, Switzerland  
11 – 12 April 2018

### Summary of decisions and recommendations

<table>
<thead>
<tr>
<th>Agenda item</th>
<th>Decisions, Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and opening remarks</td>
<td>• Dr Ren Minghui, Assistant Director-General for Communicable Diseases (CDS) and TDR Special Programme Coordinator, Chair of the meeting, welcomed everybody.</td>
</tr>
<tr>
<td>Greetings and updates</td>
<td>• Dr Modest Mulenga, Chair of the Joint Coordinating Board (JCB), Professor Charles Mgone, Chair of the TDR Scientific and Technical Advisory Committee (STAC) and Dr John Reeder, Director, TDR, greeted everyone and thanked WHO for hosting the meeting.</td>
</tr>
</tbody>
</table>
| Follow-up to the 102nd session of the Standing Committee (SC) and recommendations from JCB40         | • Welcomed the report on follow-ups to the recommendations of the 102nd session of the SC which were fully implemented or are on track.  
• Thanked the ADG/CDS and TDR Special Programme Coordinator for following up the discussions with WHO’s senior leadership on key issues and requested a continued dialogue, especially on staff mobility and resource mobilization efforts at WHO. |
| Update on TDR activities and recommendations from STAC40                                              | • Welcomed and endorsed the Director’s report on progress and key achievements in 2016-17 and successful commencement of the new TDR strategy.  
• Welcomed the fact that the new strategy is well aligned with the priorities of WHO’s GPW13 and the strategic plans of all TDR co-sponsors.  
• Welcomed the report from Chair STAC which provided an overview of the 2018 STAC meeting, 2017 SWG meetings and technical recommendations made to support implementation of the strategy.  
• Recommended continued engagement to identify the best ways for TDR to add value in support of broader outbreak/emergency response activities through its implementation research expertise.  
• Recommended continuing to enhance communication efforts with current and potential funders.  
• Recommended utilizing the message from Chair JCB to highlight key achievements as well as outlining main decisions/recommendations expected from JCB members at the upcoming meeting. |
• Endorsed the TDR results report  
• Endorsed the Risk Management Report                                                                 |

TDR/SC103/18.3
<table>
<thead>
<tr>
<th><strong>Agenda item</strong></th>
<th><strong>Decisions, Recommendations</strong></th>
</tr>
</thead>
</table>
| **Performance overview and new Performance Framework 2018-2023** | • Welcomed the consultation process in the development of the new TDR Performance Framework 2018-2023 and the focus on how it contributes to global impact and SDGs.  
• Endorsed the TDR Performance Framework 2018-2023 |
| **News from the TDR co-sponsors** | • Welcomed the efforts made to engage with key global health initiatives by articulating TDR’s added value and requested continued engagement, particularly with the African CDC.  
• Requested co-sponsors to continue to work closely with TDR on key issues of common interest, such as AMR, TB, immunization and others.  
• Welcomed the opportunity for all TDR co-sponsors to work on the implementation research/science initiative in support of UHC goals and requested that TDR continue to work with all co-sponsors as this initiative develops.  
• Requested continued active engagement by TDR to improve coherence across implementation research capacity building initiatives of key players. |
| **Preparations for JCB41 in June 2018 and other governance updates** | • Welcomed the plans for the JCB in June and requested that the meeting be used as an opportunity to engage with TDR funders and raise the profile of TDR activities via targeted communications. |
| **Any other business** | • Agreed to hold a teleconference of the SC on 17 July 2018 and, if necessary, a meeting on 8-9 November at the WHO office in New York. |

**Participants**

**Members**
- Dr Debra Jackson, UNICEF
- Mr Tenu Avafia, UNDP
- Dr David Wilson, World Bank
- Dr Ren Minghui, WHO (Chair)
- Dr Modest Mulenga, Chair JCB
- Dr Vic Arendt, Vice-Chair JCB
- Dr Sue Kinn, representative of the JCB resource contributor group
- Dr Brice Wilfried Bicaba, representative of the JCB disease endemic country group
- Professor Charles Mgone, Chair STAC

**Special Programme (TDR)**
- Dr John Reeder, Director
- Dr Garry Aslanyan, Manager of Partnerships and Governance
- Dr Beatrice Halpaap, Portfolio and Programme Manager

---

1 Not able to attend